Your browser doesn't support javascript.
loading
Synbiotics-supplemented amino acid-based formula supports adequate growth in cow's milk allergic infants.
Burks, A Wesley; Harthoorn, Lucien F; Van Ampting, Marleen T J; Oude Nijhuis, Manon M; Langford, Jane E; Wopereis, Harm; Goldberg, Steven B; Ong, Peck Y; Essink, Brandon J; Scott, Robert B; Harvey, Bryan M.
Afiliação
  • Burks AW; University of North Carolina, Chapel Hill, NC, USA.
  • Harthoorn LF; Nutricia Research, Nutricia Advanced Medical Nutrition, Utrecht, The Netherlands.
  • Van Ampting MT; Nutricia Research, Nutricia Advanced Medical Nutrition, Utrecht, The Netherlands.
  • Oude Nijhuis MM; Nutricia Advanced Medical Nutrition, Liverpool, UK.
  • Langford JE; Nutricia Research, Nutricia Advanced Medical Nutrition, Utrecht, The Netherlands.
  • Wopereis H; Nutricia Advanced Medical Nutrition, Liverpool, UK.
  • Goldberg SB; Nutricia Research, Nutricia Advanced Medical Nutrition, Utrecht, The Netherlands.
  • Ong PY; Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands.
  • Essink BJ; Visions Clinical Research, Tucson, AZ, USA.
  • Scott RB; Children's Hospital Los Angeles/University of Southern California, Los Angeles, CA, USA.
  • Harvey BM; Meridian Clinical Research, Omaha, NE, USA.
Pediatr Allergy Immunol ; 26(4): 316-22, 2015 Jun.
Article em En | MEDLINE | ID: mdl-25845680
ABSTRACT

BACKGROUND:

Children with cow's milk allergy (CMA) are at risk for inadequate nutritional intake and growth. Dietary management of CMA, therefore, requires diets that are not only hypoallergenic but also support adequate growth in this population. This study assessed growth of CMA infants when using a new amino acid-based formula (AAF) with prebiotics and probiotics (synbiotics) and evaluated its safety in the intended population.

METHODS:

In a prospective, randomized, double-blind controlled study, full-term infants with diagnosed CMA received either an AAF (control; n = 56) or AAF with synbiotics (oligofructose, long-chain inulin, acidic oligosaccharides, Bifidobacterium breve M-16V) (test; n = 54) for 16 wk. Primary outcome was growth, measured as weight, length and head circumference. Secondary outcomes included allergic symptoms and stool characteristics.

RESULTS:

Average age (±SD) of infants at inclusion was 4.5 ± 2.4 months. Both formulas equally supported growth according to WHO 2006 growth charts and resulted in similar increases of weight, length and head circumference. At week 16, differences (90% CI) in Z-scores (test-control) were as follows weight 0.147 (-0.10; 0.39, p = 0.32), length -0.299 (-0.69; 0.09, p = 0.21) and head circumference 0.152 (-0.15; 0.45, p = 0.40). Weight-for-age and length-for-age Z-scores were not significantly different between the test and control groups. Both formulas were well tolerated and reduced allergic symptoms; the number of adverse events was not different between the groups.

CONCLUSIONS:

This is the first study that shows that an AAF with a specific synbiotic blend, suitable for CMA infants, supports normal growth and growth similar to the AAF without synbiotics. This clinical trial is registered as NCT00664768.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos da Nutrição do Lactente / Desenvolvimento Infantil / Hipersensibilidade a Leite / Fórmulas Infantis / Simbióticos Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos da Nutrição do Lactente / Desenvolvimento Infantil / Hipersensibilidade a Leite / Fórmulas Infantis / Simbióticos Idioma: En Ano de publicação: 2015 Tipo de documento: Article